The Parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells

Stem Cells and Development

Volumn 22, Issue 18, 2013, Pages 2487-2496

  Bahnassawy, Lamia'A ^a,b,c   Nicklas, Sarah ^a,b,c   Palm, Thomas ^a,b   Menzl, Ingeborg ^a,b   Birzele, Fabian ^d   Gillardon, Frank ^d   Schwamborn, Jens C ^a,b,c  

^a ZMBE   (Germany)

^b Interdisciplinary Center for Clinical Research (IZKF)   (Germany)

^c UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; LEUCINE RICH REPEAT KINASE 2; MICRORNA; MICRORNA 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GEL ELECTROPHORESIS; GENE EXPRESSION PROFILING; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; KNOCKOUT MOUSE; LUMINESCENCE; MITOCHONDRION; MOUSE; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; CELL SURVIVAL; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; DOWN-REGULATION; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; MITOCHONDRIA; MUTATION; NEURAL STEM CELLS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE ANALYSIS, DNA; UP-REGULATION;

EID: 84883416205     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0163     Document Type: Article

References (49)

1. Gandhi PN, SG Chen and AL Wilson-Delfosse. (2009). Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J Neurosci Res 87:1283-1295.
2. de Rijk MC, LJ Launer, K Berger, MM Breteler, JF Dartigues, M Baldereschi, L Fratiglioni, A Lobo, J Martinez-Lage, C Trenkwalder and A Hofman. (2000). Prevalence of Parkinson's disease in Europe: a collaborative study of populationbased cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S21-S23.
3. Abeliovich A and M Flint Beal. (2006). Parkinsonism genes: culprits and clues. J Neurochem 99:1062-1072.
4. Healy DG, NW Wood and AH Schapira. (2008). Test for LRRK2 mutations in patients with Parkinson's disease. Pract Neurol 8:381-385.
5. Dachsel JC, K Nishioka, C Vilarino-Guell, SJ Lincoln, AI Soto-Ortolaza, J Kachergus, KM Hinkle, MG Heckman, B Jasinska-Myga, et al. (2010). Heterodimerization of Lrrk1-Lrrk2: implications for LRRK2-associated Parkinson disease. Mech Ageing Dev 131:210-214.
6. Zimprich A, S Biskup, P Leitner, P Lichtner, M Farrer, S Lincoln, J Kachergus, M Hulihan, RJ Uitti, et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607.
7. Paisan-Ruiz C, S Jain, EW Evans, WP Gilks, J Simon, M van der Brug, A Lopez de Munain, S Aparicio, AM Gil, et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600.
8. Mata IF, WJ Wedemeyer, MJ Farrer, JP Taylor and KA Gallo. (2006). LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29: 286-293.
9. Melrose H, S Lincoln, G Tyndall, D Dickson and M Farrer. (2006). Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139:791-794.
10. Deng J, PA Lewis, E Greggio, E Sluch, A Beilina and MR Cookson. (2008). Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci USA 105: 1499-1504.
11. Li X, YC Tan, S Poulose, CW Olanow, XY Huang and Z Yue. (2007). Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103: 238-247.
12. West AB, DJ Moore, S Biskup, A Bugayenko,WWSmith, CA Ross, VL Dawson and TM Dawson. (2005). Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102: 16842-16847.
13. Biskup S, DJ Moore, F Celsi, S Higashi, AB West, SA Andrabi, K Kurkinen, SW Yu, JM Savitt, et al. (2006). Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60: 557-569.
14. Taymans JM, C Van den Haute and V Baekelandt. (2006). Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 98:951-961.
15. Higashi S, S Biskup, AB West, D Trinkaus, VL Dawson, RL Faull, HJ Waldvogel, H Arai, TM Dawson, DJ Moore and PC Emson. (2007). Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 1155:208-219.
16. Andres-Mateos E, R Mejias, M Sasaki, X Li, BM Lin, S Biskup, L Zhang, R Banerjee, B Thomas, et al. (2009). Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci 29:15846-15850.
17. Zechel S, A Meinhardt, K Unsicker and O von Bohlen Und Halbach. (2010). Expression of leucine-rich-repeat-kinase 2 (LRRK2) during embryonic development. Int J Dev Neurosci 28:391-399.
18. Worlitzer MM, EC Bunk, K Hemmer and JC Schwamborn. (2012). Anti-Inflammatory treatment induced regenerative oligodendrogenesis in parkinsonian mice. Stem Cell Res Ther 3:33.
19. Li Y, W Liu, TF Oo, L Wang, Y Tang, V Jackson-Lewis, C Zhou, K Geghman, M Bogdanov, et al. (2009). Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12:826-828.
20. Mortazavi A, BA Williams, K McCue, L Schaeffer and B Wold. (2008). Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5:621-628.
21. Szklarczyk D, A Franceschini, M Kuhn, M Simonovic, A Roth, P Minguez, T Doerks, M Stark, J Muller, et al. (2011). The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39:D561-D568.
22. Conti L and E Cattaneo. (2010). Neural stem cell systems: physiological players or in vitro entities Nat Rev Neurosci 11:176-187.
23. Glaser T, T Opitz, T Kischlat, R Konang, P Sasse, BK Fleischmann, W Engel, K Nayernia and O Brustle. (2008). Adult germ line stem cells as a source of functional neurons and glia. Stem Cells 26:2434-2443.
24. Milosevic J, SC Schwarz, V Ogunlade, AK Meyer, A Storch and J Schwarz. (2009). Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol Neurodegener 4:25.
25. Conti L, SM Pollard, T Gorba, E Reitano, M Toselli, G Biella, Y Sun, S Sanzone, QL Ying, E Cattaneo and A Smith. (2005). Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol 3:e283.
26. Gehrke S, Y Imai, N Sokol and B Lu. (2010). Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466:637-641.
27. Leucht C, C Stigloher, A Wizenmann, R Klafke, A Folchert and L Bally-Cuif. (2008). MicroRNA-9 directs late organizer activity of the midbrain-hindbrain boundary. Nat Neurosci 11:641-648.
28. Zhao C, G Sun, S Li and Y Shi. (2009). A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination. Nat Struct Mol Biol 16:365-371.
29. Han SS, LA Williams and KC Eggan. (2011). Constructing and deconstructing stem cell models of neurological disease. Neuron 70:626-644.
30. Hanna J, M Wernig, S Markoulaki, CW Sun, A Meissner, JP Cassady, C Beard, T Brambrink, LC Wu, TM Townes and R Jaenisch. (2007). Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318:1920-1923.
31. Raya A, I Rodriguez-Piza, G Guenechea, R Vassena, S Navarro, MJ Barrero, A Consiglio, M Castella, P Rio, et al. (2009). Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460:53-59.
32. Chang T, W Zheng, WTsark, SE Bates, H Huang, RJ Lin and JK Yee. (2011). Phenotypic Rescue of Induced Pluripotent Stem Cell-Derived Motoneurons of a Spinal Muscular Atrophy Patient. Stem Cells.
33. Winner B, HL Melrose, C Zhao, KM Hinkle, M Yue, C Kent, AT Braithwaite, S Ogholikhan, R Aigner, et al. (2011). Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis 41:706-716.
34. Schwamborn JC, E Berezikov and JA Knoblich. (2009). The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell 136:913-925.
35. Zhao C, G Sun, S Li, MF Lang, S Yang, W Li and Y Shi. (2010). MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Proc Natl Acad Sci USA 107:1876-1881.
36. Daniels V, V Baekelandt and JM Taymans. (2011). On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies. Neurosignals 19:1-15.
37. de Castro IP, LM Martins and SH Loh. (2011). Mitochondrial quality control and Parkinson's disease: a pathway unfolds. Mol Neurobiol 43:80-86.
38. Burbulla LF, G Krebiehl and R Kruger. (2010). Balance is the challenge-the impact of mitochondrial dynamics in Parkinson's disease. Eur J Clin Invest 40:1048-1060.
39. Surmeier DJ, JN Guzman, J Sanchez-Padilla and JA Goldberg. (2011). The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal 14:1289-1301.
40. Cuervo AM, ES Wong and M Martinez-Vicente. (2010). Protein degradation, aggregation, and misfolding. Mov Disord 25 Suppl 1:S49-S54.
41. Shadrina MI, PA Slominsky and SA Limborska. (2010). Molecular mechanisms of pathogenesis of Parkinson's disease. Int Rev Cell Mol Biol 281:229-266.
42. Zabel C, HP Nguyen, SC Hin, D Hartl, L Mao and J Klose. (2010). Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders. J Proteomics 73:2230-2238.
43. Bingol B and M Sheng. (2011). Deconstruction for reconstruction: the role of proteolysis in neural plasticity and disease. Neuron 69:22-32.
44. Kalia SK, LV Kalia and PJ McLean. (2010). Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord Drug Targets 9:741-753.
45. Nguyen HN, B Byers, B Cord, A Shcheglovitov, J Byrne, P Gujar, K Kee, B Schule, RE Dolmetsch, et al. (2011). LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8:267-280.
46. Hoglinger GU, JJ Breunig, C Depboylu, C Rouaux, PP Michel, D Alvarez-Fischer, AL Boutillier, J Degregori, WH Oertel, et al. (2007). The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci USA 104:3585-3590.
47. Palm T, L Bahnassawy and J Schwamborn. (2012). miRNAs and neural stem cells: a team to treat Parkinson's disease RNA Biol 9:720-730.
48. Liou AK, RK Leak, L Li and MJ Zigmond. (2008). Wildtype LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol Dis 32:116-124.
49. Carballo-Carbajal I, S Weber-Endress, G Rovelli, D Chan, B Wolozin, CL Klein, N Patenge, T Gasser and PJ Kahle. (2010). Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal 22:821-827.